期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
A probiotic treatment containing Lactobacillus,Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial 被引量:33
1
作者 FAN yu-jing CHEN Shu-jie +2 位作者 YU Ying-cong SI Jian-min LIU Bin 《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 SCIE CAS CSCD 2006年第12期987-991,共5页
Objective: To evaluate the efficacy and safety of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules in treatment of irritable bowel syndrome, Methods: Eighty-fve patients [male 32, female 53; a... Objective: To evaluate the efficacy and safety of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules in treatment of irritable bowel syndrome, Methods: Eighty-fve patients [male 32, female 53; age (45.31±11,72) years] were given live combined Bifidobacterium, Lactobacillus and Enterococcus capsules 1260 mg/d t.i.d. ×4 weeks. Syndrome scales were used to evaluate the efficacy in gastrointestinal syndrome. Fecal flora was also measured before and after the treatment. Six bacteria were cultured and the colony forming units were counted in stool. SPSS was used for data analysis. Results: Seventy-four patients finished the follow-up. No side-effect was found. For treatment of irritable bowel syndrome, the effective rate of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules was 56.8% in the second week, 74.3% in the fourth week and 73.0% in the sixth week. Single symptom was improved, especially in abdominal pain and stool character. The probiotica containing live combined Bifidobacterium, Lactobacillus and Enterococcus could increase bifidobacterium count (P〈0.01) and lactobacillus count (P〈0.05); decrease bacteroides count (P〈0.05) and enterococci count (P〈0.01); No obvious changes were observed in clostridium diffcile colonitis and enterobacteriaceae (P〉0.05). Conclusion: The result of the study indicated that the administration of live combined Bifidobacterium, Lactobacillus and Enterococcus improved the symptom of irritable bowel syndrome and that there was a gradual increase of this effect. Thereafter conditions remained stable for 2 weeks. That improvement may be associated with alterations in gastrointestinal flora. 展开更多
关键词 Irritable bowel syndrome (IBS) Intestinal flora probiotic agents
下载PDF
Effect of special Hungarian probiotic kefir on faecal microflora
2
作者 MáriaFigler GyulaMózsik +5 位作者 BélaSchaffer BeátaGasztonyi Pongrác cs BélaSzili Regina Rab SándorSzakály 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第7期1129-1132,共4页
AIM: To investigate the effect of a four-week consumption of a special Hungarian probiotic agent (Biofir) on the faecal microflora in human healthy subjects.METHODS: The effect of Biofir with 10^6/cm^3 initial ger... AIM: To investigate the effect of a four-week consumption of a special Hungarian probiotic agent (Biofir) on the faecal microflora in human healthy subjects.METHODS: The effect of Biofir with 10^6/cm^3 initial germs on the faecal microflora was studied in 120 healthy volunteers (71 females, 49 males). The traditional Russian type kefir was used as control. The various germ groups and pH values were determined in wk 2, 4 and 6.RESULTS: The number of all microbes increased during the 4-week probiotic treatment. The number of microbes increased 4,3-fold in the control group and 6.8-fold in Biofir-treated group. The probiotic kefir caused multiplication of the probiotic flora, meanwhile the undesired bacteria multiplied in the control group. No significant change of pH values of the faeces was found in both groups.CONCLUSION: The Hungarian probiotic keflr (Biofir) is capable of promoting multiplication of probiotic bacterial flora in the large bowel. 展开更多
关键词 Hungarian probiotic agent (Biofir) Faecal microflora Large bowel
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部